Recruitment status changed
Before: Enrolling by invitation. After: Recruiting.
Study sponsor: Satellos Bioscience, Inc. · MSLE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: Enrolling by invitation. After: Recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 24 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 24 months. After: Measure: Treatment emergent adverse events Description: Incidence, temporal profile, and severity of treatment emergent adverse events (TEAEs) Time frame: 12 months Measure: SAT-3247 effect on fat fraction in biceps brachii Description: Changes from baseline in intramuscular fat fraction in muscle quantitative magnetic resonance (qMR) in biceps brachii following treatment with SAT-3247. Time frame: 12 months.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Treatment emergent adverse events. After: Measure: Treatment emergent adverse events Measure: SAT-3247 effect on fat fraction in biceps brachii.
Before: 10 participants (planned). After: 30 participants (planned).
Before: 30 Aug 2026. After: 30 Sep 2027.